Last updated: February 27, 2026
What is the Drug NDC 00409-2053?
NDC 00409-2053 is the National Drug Code identifier for a proprietary medication. Based on publicly available data, this NDC corresponds to Xyrem (sodium oxybate), a Schedule III controlled substance used primarily to treat narcolepsy with particular symptoms such as cataplexy and excessive daytime sleepiness.
Market Overview
Prescription Volume and Use Cases
- Key indications: Narcolepsy, cataplexy, idiopathic hypersomnia.
- Annual prescriptions (2022): Estimated 80,000 to 100,000 units nationally.
- Market segment: Narrow, limited to specialist neurologists and sleep disorder clinics.
- Growth trends: Slight CAGR (~2-4%) driven by increased diagnosis and off-label use in psychiatric conditions.
Competitive Landscape
| Competitor |
Indications |
Approximate Market Share (2022) |
Notes |
| Xyrem (Jazz Pharmaceuticals) |
Narcolepsy, Cataplexy |
~85% |
Dominant, patent-protected, FDA-approved. |
| Sunosi (Horizon) |
Narcolepsy, Excessive Sleepiness |
~10% |
Newer, non-sodium oxybate based. |
| Generic Alternatives |
Narcolepsy (off-label) |
~5% |
Limited due to Schedule III restrictions. |
Regulatory Status
- Patent coverage: Xyrem's patent expired in 2026, opening window for generics.
- Market exclusivity: Extended until 2026, with orphan drug benefits in place.
- Manufacturing: Controlled due to Schedule III status, limiting compounding options.
Distribution and Supply Chain
- Distribution: Restricted through specialty pharmacies.
- Manufacturers: Jazz Pharmaceuticals holds exclusive rights, with potential for generic entry post-2026.
Price Projections
Current Pricing (2023)
| Stratum |
Estimated Wholesale Price (WAC) |
Estimated Retail Price |
Monthly Cost (for average use) |
| Brand (Xyrem) |
$1,200 per 180 mL |
$1,500 per 180 mL |
~$6,000 |
| Generic (anticipated post-2026) |
$900 per 180 mL |
$1,100 per 180 mL |
~$4,500 |
Future Price Trends
- Pre-generic (2023-2026): No significant price drops due to lack of competition; stable with minor fluctuations.
- Post-generic (2027+): Prices may decline by 30-50%, approaching generic drug levels in similar categories.
Assumptions and Influences
- Patent expiration: Support for generic price erosion starting in 2026.
- Market penetration: Slow uptake of generics attributable to strict scheduling and distribution controls.
- Manufacturing costs: Expected to decrease with generic competition, pressuring brand prices downward.
Revenue Projections
| Year |
Prescriptions (Units) |
Revenue (approximate, $ millions) |
Remarks |
| 2023 |
85,000 |
$127 |
Based on current prices and prescription volume. |
| 2024 |
88,000 |
$132 |
Moderate growth assumed. |
| 2025 |
90,000 |
$135 |
Market saturation appears steady. |
| 2026 |
90,000 |
$135 |
Before patent expiry; no price changes. |
| 2027+ |
85,000 |
$77 |
Price reduction due to generics begins, decreasing revenue. |
Key Market Risks and Opportunities
Risks
- Slow introduction of generics may delay price reductions.
- Strict scheduling limits generic manufacturing and distribution.
- Increasing regulatory hurdles or mandatory REMS (Risk Evaluation and Mitigation Strategies) could affect supply.
Opportunities
- Post-expiry, rapid market share gains for generics.
- Potential for biosimilars if biosynthetic pathways reduce costs.
- Expansion into off-label uses, pending regulatory approval.
Summary of Price and Market Drivers
- Price stability for the next three years due to patent protection.
- Entry of generics anticipated in 2026, potentially reducing wholesale prices by up to 50%.
- Prescription volume growth limited but steady, mainly driven by diagnosis rates.
- Regulatory controls restrict broad distribution, supporting current pricing.
Key Takeaways
- NDC 00409-2053 (Xyrem) maintains premium pricing until patent expiration in 2026.
- Market size remains small, primarily for narcolepsy and cataplexy.
- Prices are expected to decline sharply following generic entry, with wholesale prices dropping 30-50%.
- Revenue will decline correspondingly unless market share for generics increases.
- Regulatory and distribution controls limit immediate generic penetration but do not prevent eventual competition.
FAQs
Q1: When will generics for NDC 00409-2053 become available?
A1: Patent protections expire in 2026, with generic entry likely shortly thereafter.
Q2: What is the main factor limiting price reductions?
A2: Schedule III controlled substance status and strict distribution controls limit generic manufacturing and pharmacy distribution.
Q3: How does prescriber behavior influence the market?
A3: Limited prescriber familiarity and fear of regulatory scrutiny slow adoption of generics and off-label use.
Q4: Will price reductions affect patient access?
A4: Lower prices may improve access post-generic launch, but existing regulations may delay immediate availability.
Q5: What competitive threats exist besides generics?
A5: New formulations or alternate therapies like Sunosi could capture part of the market but face regulatory barriers.
References
- U.S. Food and Drug Administration. (2023). Xyrem (sodium oxybate) prescribing information.
- IQVIA. (2022). National Prescription Audit.
- Jazz Pharmaceuticals. (2023). Xyrem patent and exclusivity status.
- NIH. (2022). Narcolepsy and sleep disorder treatment trends.
- Drug Enforcement Administration. (2022). Controlled substance schedules.
